RDY

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Wall Street analysts forecast RDY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDY is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Dr Reddy's Laboratories Ltd revenue for the last quarter amounts to 1.01B USD, increased 5.41 % YoY.

Dr Reddy's Laboratories Ltd. EPS for the last quarter amounts to 0.20 USD, increased 11.11 % YoY.

Dr Reddy's Laboratories Ltd (RDY) has 27811 emplpoyees as of December 16 2025.

Today RDY has the market capitalization of 11.73B USD.